India · Delayed Price · Currency is INR Biocon Statistics
Total Valuation
Biocon has a market cap or net worth of INR 673.32 billion. The enterprise value is 814.73 billion.
| Market Cap | 673.32B |
| Enterprise Value | 814.73B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | Jul 3, 2026 |
Share Statistics
Biocon has 1.62 billion shares outstanding. The number of shares has increased by 14.12% in one year.
| Current Share Class | 1.62B |
| Shares Outstanding | 1.62B |
| Shares Change (YoY) | +14.12% |
| Shares Change (QoQ) | +18.58% |
| Owned by Insiders (%) | 46.00% |
| Owned by Institutions (%) | 23.71% |
| Float | 708.71M |
Valuation Ratios
The trailing PE ratio is 147.54 and the forward PE ratio is 51.36. Biocon's PEG ratio is 0.74.
| PE Ratio | 147.54 |
| Forward PE | 51.36 |
| PS Ratio | 3.98 |
| PB Ratio | 1.84 |
| P/TBV Ratio | 12.89 |
| P/FCF Ratio | 343.36 |
| P/OCF Ratio | 33.77 |
| PEG Ratio | 0.74 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.58, with an EV/FCF ratio of 415.47.
| EV / Earnings | 211.29 |
| EV / Sales | 4.81 |
| EV / EBITDA | 23.58 |
| EV / EBIT | 54.37 |
| EV / FCF | 415.47 |
Financial Position
The company has a current ratio of 1.22, with a Debt / Equity ratio of 0.42.
| Current Ratio | 1.22 |
| Quick Ratio | 0.70 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 4.47 |
| Debt / FCF | 78.71 |
| Interest Coverage | 1.51 |
Financial Efficiency
Return on equity (ROE) is 1.15% and return on invested capital (ROIC) is 2.69%.
| Return on Equity (ROE) | 1.15% |
| Return on Assets (ROA) | 1.53% |
| Return on Invested Capital (ROIC) | 2.69% |
| Return on Capital Employed (ROCE) | 3.02% |
| Weighted Average Cost of Capital (WACC) | 5.85% |
| Revenue Per Employee | 10.31M |
| Profits Per Employee | 234,836 |
| Employee Count | 16,420 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 1.03 |
Taxes
In the past 12 months, Biocon has paid 791.00 million in taxes.
| Income Tax | 791.00M |
| Effective Tax Rate | 17.66% |
Stock Price Statistics
The stock price has increased by +17.07% in the last 52 weeks. The beta is 0.31, so Biocon's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +17.07% |
| 50-Day Moving Average | 389.51 |
| 200-Day Moving Average | 379.48 |
| Relative Strength Index (RSI) | 54.74 |
| Average Volume (20 Days) | 3,369,266 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biocon had revenue of INR 169.27 billion and earned 3.86 billion in profits. Earnings per share was 2.82.
| Revenue | 169.27B |
| Gross Profit | 112.36B |
| Operating Income | 14.99B |
| Pretax Income | 4.48B |
| Net Income | 3.86B |
| EBITDA | 34.55B |
| EBIT | 14.99B |
| Earnings Per Share (EPS) | 2.82 |
Balance Sheet
The company has 38.83 billion in cash and 154.34 billion in debt, with a net cash position of -115.51 billion or -71.37 per share.
| Cash & Cash Equivalents | 38.83B |
| Total Debt | 154.34B |
| Net Cash | -115.51B |
| Net Cash Per Share | -71.37 |
| Equity (Book Value) | 366.22B |
| Book Value Per Share | 213.54 |
| Working Capital | 31.11B |
Cash Flow
In the last 12 months, operating cash flow was 19.94 billion and capital expenditures -17.98 billion, giving a free cash flow of 1.96 billion.
| Operating Cash Flow | 19.94B |
| Capital Expenditures | -17.98B |
| Depreciation & Amortization | 19.57B |
| Net Borrowing | -46.69B |
| Free Cash Flow | 1.96B |
| FCF Per Share | 1.21 |
Margins
Gross margin is 66.38%, with operating and profit margins of 8.85% and 2.28%.
| Gross Margin | 66.38% |
| Operating Margin | 8.85% |
| Pretax Margin | 2.65% |
| Profit Margin | 2.28% |
| EBITDA Margin | 20.41% |
| EBIT Margin | 8.85% |
| FCF Margin | 1.16% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 0.12%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 0.12% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 23.55% |
| Buyback Yield | -14.12% |
| Shareholder Yield | -14.00% |
| Earnings Yield | 0.57% |
| FCF Yield | 0.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Biocon is 414.05, which is -1.15% lower than the current price. The consensus rating is "Buy".
| Price Target | 414.05 |
| Price Target Difference | -1.15% |
| Analyst Consensus | Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | 13.75% |
| EPS Growth Forecast (3Y) | 34.45% |
Stock Splits
The last stock split was on June 12, 2019. It was a forward split with a ratio of 2.
| Last Split Date | Jun 12, 2019 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 8 |